Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Bladder Cancer

  Free Subscription


02.04.2018

1 Acta Med Port
1 Am J Chin Med
2 Anticancer Res
2 BJU Int
1 BMC Res Notes
1 BMJ Open
1 Can Urol Assoc J
1 Cancer Immunol Res
1 Cancer Invest
1 Cancer Med
2 Clin Genitourin Cancer
1 Eur Urol
1 Int J Urol
1 J Cancer
2 J Cancer Res Ther
1 J Food Drug Anal
1 Jpn J Clin Oncol
1 Minerva Urol Nefrol
1 Nutr Cancer
4 Oncotarget
1 PLoS One
4 Urol Oncol
1 Urol Pract
1 Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Acta Med Port

  1. MOTA P, Sousa PM, Botelho F, Carvalho-Dias E, et al
    [Smoking Cessation after Bladder Cancer Diagnosis].
    Acta Med Port. 2018;31:101-108.
    PubMed     Text format     Abstract available


    Am J Chin Med

  2. KIM WT, Seo SP, Byun YJ, Kang HW, et al
    The Anticancer Effects of Garlic Extracts on Bladder Cancer Compared to Cisplatin: A Common Mechanism of Action via Centromere Protein M.
    Am J Chin Med. 2018 Mar 29:1-17. doi: 10.1142/S0192415X18500362.
    PubMed     Text format     Abstract available


    Anticancer Res

  3. KIM S, Lee AJ, Yeo MK, Na YG, et al
    Clinicopathological Profiling of LC3B, an Autophagy Marker, and ESRRA (Estrogen-related Receptor-alpha) in Muscle-invasive Bladder Cancer.
    Anticancer Res. 2018;38:2429-2437.
    PubMed     Text format     Abstract available

  4. MATSUNAGA W, Ichikawa M, Nakamura A, Ishikawa T, et al
    Lentiviral Vector-mediated Gene Transfer in Human Bladder Cancer Cell Lines.
    Anticancer Res. 2018;38:2015-2020.
    PubMed     Text format     Abstract available


    BJU Int

  5. MOSSANEN M, Brown JC, Schrag D
    Well-being beyond the bladder. How do we improve the overall health of patients with bladder cancer?
    BJU Int. 2018;121:489-491.
    PubMed     Text format    

  6. LOTAN Y, Woldu SL, Sanli O, Black P, et al
    Modeling Cost-Effectiveness of a Biomarker-Based Approach to Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
    BJU Int. 2018 Mar 31. doi: 10.1111/bju.14220.
    PubMed     Text format     Abstract available


    BMC Res Notes

  7. HASHMI AA, Hussain ZF, Irfan M, Edhi MM, et al
    Cytokeratin 5/6 expression in bladder cancer: association with clinicopathologic parameters and prognosis.
    BMC Res Notes. 2018;11:207.
    PubMed     Text format     Abstract available


    BMJ Open

  8. GISLEFOSS RE, Stenehjem JS, Hektoen HH, Andreassen BK, et al
    Vitamin D, obesity and leptin in relation to bladder cancer incidence and survival: prospective protocol study.
    BMJ Open. 2018;8:e019309.
    PubMed     Text format     Abstract available


    Can Urol Assoc J

  9. KASSOUF W, Aprikian A, Saad F, Breau RH, et al
    Improving patient journey and quality of care: Summary from the 2nd Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.
    Can Urol Assoc J. 2018 Mar 19. pii: cuaj.5246. doi: 10.5489/cuaj.5246.
    PubMed     Text format    


    Cancer Immunol Res

  10. WINERDAL ME, Krantz D, Hartana CA, Zirakzadeh AA, et al
    Urinary Bladder Cancer Tregs Suppress MMP2 and Potentially Regulate Invasiveness.
    Cancer Immunol Res. 2018 Mar 27. pii: 2326-6066.CIR-17-0466.
    PubMed     Text format     Abstract available


    Cancer Invest

  11. TOMISAKI I, Kubo T, Minato A, Fujimoto N, et al
    Efficacy and Tolerability of Bacillus Calmette-Guerin Therapy as the First-Line Therapy for Upper Urinary Tract Carcinoma In Situ.
    Cancer Invest. 2018;36:152-157.
    PubMed     Text format     Abstract available


    Cancer Med

  12. CHEN Y, Wang H, Zuo Y, Li N, et al
    A novel monoclonal antibody KMP1 has potential antitumor activity of bladder cancer by blocking CD44 in vivo and in vitro.
    Cancer Med. 2018 Mar 25. doi: 10.1002/cam4.1446.
    PubMed     Text format     Abstract available


    Clin Genitourin Cancer

  13. KANG HW, Seo SP, Byun YJ, Piao XM, et al
    Molecular Progression Risk Score for Prediction of Muscle Invasion in Primary T1 High-Grade Bladder Cancer.
    Clin Genitourin Cancer. 2018 Feb 23. pii: S1558-7673(18)30117.
    PubMed     Text format     Abstract available

  14. KOSHKIN VS, Barata PC, Rybicki LA, Zahoor H, et al
    Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function.
    Clin Genitourin Cancer. 2018 Feb 22. pii: S1558-7673(18)30118.
    PubMed     Text format     Abstract available


    Eur Urol

  15. SARFATY M, Hall PS, Chan KKW, Virik K, et al
    Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer.
    Eur Urol. 2018 Mar 22. pii: S0302-2838(18)30182.
    PubMed     Text format     Abstract available


    Int J Urol

  16. TATSUGAMI K
    Editorial Comment to Prediction models for progression of non-muscle-invasive bladder cancer: A review.
    Int J Urol. 2018;25:218-219.
    PubMed     Text format    


    J Cancer

  17. HUANG L, Luan T, Chen Y, Bao X, et al
    LASS2 regulates invasion and chemoresistance via ERK/Drp1 modulated mitochondrial dynamics in bladder cancer cells.
    J Cancer. 2018;9:1017-1024.
    PubMed     Text format     Abstract available


    J Cancer Res Ther

  18. LIU TJ, Zhang JC, Gao XZ, Tan ZB, et al
    Clinical research of goal-directed fluid therapy in elderly patients with radical resection of bladder cancer.
    J Cancer Res Ther. 2018;14.
    PubMed     Text format     Abstract available

  19. WU GJ, Bao JS, Yue ZJ, Zeng FC, et al
    Elevated expression of matrix metalloproteinase-9 is associated with bladder cancer pathogenesis.
    J Cancer Res Ther. 2018;14.
    PubMed     Text format     Abstract available


    J Food Drug Anal

  20. LIAO CC, Chen SC, Huang HP, Wang CJ, et al
    Gallic acid inhibits bladder cancer cell proliferation and migration via regulating fatty acid synthase (FAS).
    J Food Drug Anal. 2018;26:620-627.
    PubMed     Text format     Abstract available


    Jpn J Clin Oncol

  21. MIYAMOTO K, Ito A, Wakabayashi M, Eba J, et al
    A Phase III trial of a single early intravesical instillation of pirarubicin to prevent bladder recurrence after radical nephroureterectomy for upper tract urothelial carcinoma (JCOG1403, UTUC THP Phase III).
    Jpn J Clin Oncol. 2018;48:94-97.
    PubMed     Text format     Abstract available


    Minerva Urol Nefrol

  22. LI Z, Niu Y
    Association between lncRNA H19 (rs217727, rs2735971 and rs3024270) polymorphisms and the risk of bladder cancer in Chinese population.
    Minerva Urol Nefrol. 2018 Mar 28. pii: S0393-2249.18.03004.
    PubMed     Text format     Abstract available


    Nutr Cancer

  23. ROSATO V, Negri E, Serraino D, Montella M, et al
    Processed Meat and Risk of Renal Cell and Bladder Cancers.
    Nutr Cancer. 2018 Mar 23:1-7. doi: 10.1080/01635581.2018.1445764.
    PubMed     Text format     Abstract available


    Oncotarget

  24. LEE MY, Yeon A, Shahid M, Cho E, et al
    Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance.
    Oncotarget. 2018;9:13231-13243.
    PubMed     Text format     Abstract available

  25. LIAN J, Lin SH, Ye Y, Chang DW, et al
    Serum microRNAs as predictors of risk for non-muscle invasive bladder cancer.
    Oncotarget. 2018;9:14895-14908.
    PubMed     Text format     Abstract available

  26. ECKSTEIN M, Wirtz RM, Pfannstil C, Wach S, et al
    A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy.
    Oncotarget. 2018;9:15001-15014.
    PubMed     Text format     Abstract available

  27. KIM WT, Kim YH, Jeong P, Seo SP, et al
    Urinary cell-free nucleic acid IQGAP3: a new non-invasive diagnostic marker for bladder cancer.
    Oncotarget. 2018;9:14354-14365.
    PubMed     Text format     Abstract available


    PLoS One

  28. BARBOSA ALA, Vermeulen SHHM, Aben KK, Grotenhuis AJ, et al
    Smoking intensity and bladder cancer aggressiveness at diagnosis.
    PLoS One. 2018;13:e0194039.
    PubMed     Text format     Abstract available


    Urol Oncol

  29. AUDENET F, Attalla K, Sfakianos JP
    The evolution of bladder cancer genomics: What have we learned and how can we use it?
    Urol Oncol. 2018 Mar 21. pii: S1078-1439(18)30074.
    PubMed     Text format     Abstract available

  30. ZHAO J, Shi L, Zeng S, Ma C, et al
    Importin-11 overexpression promotes the migration, invasion, and progression of bladder cancer associated with the deregulation of CDKN1A and THBS1.
    Urol Oncol. 2018 Mar 27. pii: S1078-1439(18)30077.
    PubMed     Text format     Abstract available

  31. MOSCHINI M, Arbelaez E, Cornelius J, Mattei A, et al
    Pattern of node metastases in patients treated with radical cystectomy and extended or superextended pelvic lymph node dissection due to bladder cancer.
    Urol Oncol. 2018 Mar 27. pii: S1078-1439(18)30078.
    PubMed     Text format     Abstract available

  32. LI Q, Li C, Chen J, Liu P, et al
    High expression of long noncoding RNA NORAD indicates a poor prognosis and promotes clinical progression and metastasis in bladder cancer.
    Urol Oncol. 2018 Mar 28. pii: S1078-1439(18)30076.
    PubMed     Text format     Abstract available


    Urol Pract

  33. LENIS AT, Asanad K, Blaibel M, Donin NM, et al
    Association between Metabolic Syndrome and Recurrence of Nonmuscle Invasive Bladder Cancer following bacillus Calmette-Guerin Treatment.
    Urol Pract. 2018;5:132-138.
    PubMed     Text format     Abstract available


    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi

  34. WANG C, Xu Z, Li W, Jiao Y, et al
    [Analysis of the correlation between E2F3 expression and the number of tumor-infiltrating CD8(+)T cells in invasive bladder cancer tissues].
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2018;34:1-8.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: